Aside from ongoing investigations into its manufacturing operations, the FDA "is also considering additional enforcement actions against the company for its pattern of non-compliance, which may include seizure, injunction or criminal penalties," FDA principal deputy commissioner Joshua Sharfstein said.
via industryweek.com
No comments:
Post a Comment